Recent advances of cyclin-dependent kinases as potential therapeutic targets in HR+/HER2− metastatic breast cancer: a focus on ribociclib
Dumessa Edessa,1 Mekonnen Sisay2 1Department of Pharmacy Practice, 2Department of Pharmacology and Toxicology, School of Pharmacy, College of Health and Medical Sciences, Haramaya University, Oromia, Ethiopia Abstract: In normal cell cycle progression, transition of G0/G1 phase to synthesis (S) phas...
Enregistré dans:
Auteurs principaux: | Edessa D, Sisay M |
---|---|
Format: | article |
Langue: | EN |
Publié: |
Dove Medical Press
2017
|
Sujets: | |
Accès en ligne: | https://doaj.org/article/adb89baa8dbc4a39a078e6ab110d38ab |
Tags: |
Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!
|
Documents similaires
-
Fulvestrant in Combination with CDK4/6 Inhibitors for HER2- Metastatic Breast Cancers: Current Perspectives
par: Iorfida M, et autres
Publié: (2020) -
Analysis of the efficacy and safety of eribulin therapy in patients with HR+/HER2- metastatic breast cancer pretreated with CDK4/6 inhibitors in real Russian practice
par: Irina V. Kolyadina, et autres
Publié: (2021) -
Place of CDK 4/6 and PARP inhibitors in the modern treatment approach of HER2-negative breast cancer
par: Board Editorial
Publié: (2021) -
Don’t let it disappear: new opportunities to prolong the life of HR+ HER2- advanced breast cancer patients. Event review of the satellite symposium. RUSSCO Big Conference «Breast Cancer» (online). January 28th, 2021
par: Editorial Board
Publié: (2021) -
The Role of CDK4 in the Pathogenesis of Pancreatic Cancer
par: Emily Jiggens, et autres
Publié: (2021)